---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-048364"
form_type: "8-K"
ticker: "ORKA"
cik: "0000907654"
company_name: "Oruka Therapeutics, Inc."
filed_at: "2024-04-25T23:59:59+00:00"
generated_at: "2026-06-03T09:00:57.948391+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# ARCA biopharma Q1 net loss $2.0M, cash $35.9M; Oruka merger and CEO change detailed

## Summary
- Net loss for Q1 2024 was $2.0M ($0.14 per share) vs $1.3M ($0.09) in Q1 2023.
- Cash and equivalents $35.9M at March 31, 2024, down from $37.4M at Dec. 31, 2023; funds operations through mid-2025.
- G&A expenses rose to $2.3M from $1.4M due to $1.1M in professional fees related to the Oruka merger.
- CEO Michael Bristow separated effective April 3, 2024; Thomas Keuer appointed President and principal executive officer.
- Merger with Oruka Therapeutics is subject to conditions; failure could lead to dissolution or alternative strategic transaction.

## SEC filing metadata
- accession: 0000950170-24-048364
- form_type: 8-K
- ticker: ORKA
- cik: 0000907654
- company_name: Oruka Therapeutics, Inc.
- filed_at: 2024-04-25T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/907654/000095017024048364/0000950170-24-048364-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/907654/000095017024048364/abio-20240425.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-048364
- JSON: https://secwatch.observer/filing/0000950170-24-048364.json
- Plain text: https://secwatch.observer/filing/0000950170-24-048364.txt

## Key facts
- Earnings Releases
  Oruka Therapeutics, Inc. reported financial results for first quarter 2024.
  - Period: first quarter 2024
  - Result: reported results
  source text: ARCA biopharma, Inc. (Nasdaq: ABIO), (the “Company”) a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported first quarter 2024 financial results and provided a corporate update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/907654/000095017024048364/0000950170-24-048364-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.